ReviewThe Journal of clinical investigation2005
Give me A5 for lipoprotein hydrolysis!
Review in The Journal of clinical investigation, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.
- Apolipoprotein A5 gene variants and the risk of coronary heart disease: a case‑control study and meta‑analysis.Molecular medicine reports · 2013Pooled it
- Carbohydrate-dependent interaction between AMY1A/AMY2B copy number variation and APOA5 rs651821 associated with hypertriglyceridemia in Korean middle-aged adults.BMC nutrition · 2026Article
- APOA5 deficiency causes hypertriglyceridemia by reducing amounts of lipoprotein lipase in capillaries.Journal of lipid research · 2024Review
- The pathogenic mutations of APOA5 in Chinese patients with hyperlipidemic acute pancreatitis.Lipids in health and disease · 2024Article
- Apolipoprotein A-V is a potential target for treating coronary artery disease: evidence from genetic and metabolomic analyses.Journal of lipid research · 2022Article
- Lipoprotein size is a main determinant for the rate of hydrolysis by exogenous LPL in human plasma.Journal of lipid research · 2022Article
- Hypertriglyceridaemia: contemporary management of a neglected cardiovascular risk factor.Global cardiology science & practice · 2021Review
- Current Diagnosis and Management of Primary Chylomicronemia.Journal of atherosclerosis and thrombosis · 2021Review
- Metabolic-associated fatty liver disease and lipoprotein metabolism.Molecular metabolism · 2021Review
- Critical Role of SREBP-1c Large-VLDL Pathway in Environment-Induced Hypertriglyceridemia of Apo AV Deficiency.Arteriosclerosis, thrombosis, and vascular biology · 2019Article
- New insights into apolipoprotein A5 in controlling lipoprotein metabolism in obesity and the metabolic syndrome patients.Lipids in health and disease · 2018Review
- Hepatitis C virus-apolipoprotein interactions: molecular mechanisms and clinical impact.Expert review of proteomics · 2017Review
- Review
- Association of G894T eNOS, 4G/5G PAI and T1131C APOA5 polymorphisms with susceptibility to myocardial infarction in Morocco.Meta gene · 2016Article
- Exploring mechanisms of Panax notoginseng saponins in treating coronary heart disease by integrating gene interaction network and functional enrichment analysis.Chinese journal of integrative medicine · 2016Article
- Apolipoprotein A-V gene therapy for disease prevention / treatment: a critical analysis.Journal of biomedical research · 2016Review
- Haplotype analysis of the Apolipoprotein A5 gene in Moroccan patients with the metabolic syndrome.Journal of diabetes and metabolic disorders · 2015Article
- Association of APOA5 T1131C polymorphism and risk of coronary artery disease.International journal of clinical and experimental medicine · 2015Article
- Apolipoprotein A5: Extracellular and Intracellular Roles in Triglyceride Metabolism.Current drug targets · 2015Review
- Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
APOA5 is a newly identified apolipoprotein that plays a crucial role in the regulation of plasma triglyceride levels. In several human studies, common APOA5 single nucleotide polymorphisms have been strongly associated with elevated plasma triglyceride levels. In this issue of the JCI, Marçais et al. report that the rare Q139X mutation in APOA5 leads to severe hypertriglyceridemia by exerting a dominant-negative effect on the plasma lipolytic system for triglyceride-rich lipoproteins. The presented data support the idea that the molecular mechanism of APOA5 function may include the enhancement of binding between lipoproteins and proteoglycans at the vascular wall and activation of proteoglycan-bound lipoprotein lipase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.